The power of TOPMed imputation for the discovery of Latino-enriched rare variants associated with type 2 diabetes

Research output: Contribution to journalJournal articleResearchpeer-review

Documents

  • Fulltext

    Final published version, 1.95 MB, PDF document

  • Alicia Huerta-Chagoya
  • Philip Schroeder
  • Ravi Mandla
  • Aaron J. Deutsch
  • Wanying Zhu
  • Lauren Petty
  • Xiaoyan Yi
  • Joanne B. Cole
  • Miriam S. Udler
  • Peter Dornbos
  • Bianca Porneala
  • Daniel DiCorpo
  • Ching Ti Liu
  • Josephine H. Li
  • Lukasz Szczerbiński
  • Varinderpal Kaur
  • Joohyun Kim
  • Yingchang Lu
  • Alicia Martin
  • Decio L. Eizirik
  • Piero Marchetti
  • Lorella Marselli
  • Ling Chen
  • Shylaja Srinivasan
  • Jennifer Todd
  • Jason Flannick
  • Rose Gubitosi-Klug
  • Lynne Levitsky
  • Rachana Shah
  • Megan Kelsey
  • Brian Burke
  • Dana M. Dabelea
  • Jasmin Divers
  • Santica Marcovina
  • Lauren Stalbow
  • Loos, Ruth
  • Burcu F. Darst
  • Charles Kooperberg
  • Laura M. Raffield
  • Christopher Haiman
  • Quan Sun
  • Joseph B. McCormick
  • Susan P. Fisher-Hoch
  • Maria L. Ordoñez
  • James Meigs
  • Leslie J. Baier
  • Clicerio González-Villalpando
  • Maria Elena González-Villalpando
  • Lorena Orozco
  • Lourdes García-García
  • Mexican Biobank

Aims/hypothesis: The Latino population has been systematically underrepresented in large-scale genetic analyses, and previous studies have relied on the imputation of ungenotyped variants based on the 1000 Genomes (1000G) imputation panel, which results in suboptimal capture of low-frequency or Latino-enriched variants. The National Heart, Lung, and Blood Institute (NHLBI) Trans-Omics for Precision Medicine (TOPMed) released the largest multi-ancestry genotype reference panel representing a unique opportunity to analyse rare genetic variations in the Latino population. We hypothesise that a more comprehensive analysis of low/rare variation using the TOPMed panel would improve our knowledge of the genetics of type 2 diabetes in the Latino population. Methods: We evaluated the TOPMed imputation performance using genotyping array and whole-exome sequence data in six Latino cohorts. To evaluate the ability of TOPMed imputation to increase the number of identified loci, we performed a Latino type 2 diabetes genome-wide association study (GWAS) meta-analysis in 8150 individuals with type 2 diabetes and 10,735 control individuals and replicated the results in six additional cohorts including whole-genome sequence data from the All of Us cohort. Results: Compared with imputation with 1000G, the TOPMed panel improved the identification of rare and low-frequency variants. We identified 26 genome-wide significant signals including a novel variant (minor allele frequency 1.7%; OR 1.37, p=3.4 × 10−9). A Latino-tailored polygenic score constructed from our data and GWAS data from East Asian and European populations improved the prediction accuracy in a Latino target dataset, explaining up to 7.6% of the type 2 diabetes risk variance. Conclusions/interpretation: Our results demonstrate the utility of TOPMed imputation for identifying low-frequency variants in understudied populations, leading to the discovery of novel disease associations and the improvement of polygenic scores. Data availability: Full summary statistics are available through the Common Metabolic Diseases Knowledge Portal (https://t2d.hugeamp.org/downloads.html) and through the GWAS catalog (https://www.ebi.ac.uk/gwas/ , accession ID: GCST90255648). Polygenic score (PS) weights for each ancestry are available via the PGS catalog (https://www.pgscatalog.org , publication ID: PGP000445, scores IDs: PGS003443, PGS003444 and PGS003445). Graphical abstract: [Figure not available: see fulltext.]

Original languageEnglish
JournalDiabetologia
Volume66
Pages (from-to)1273-1288
Number of pages16
ISSN0012-186X
DOIs
Publication statusPublished - 2023

Bibliographical note

Publisher Copyright:
© 2023, The Author(s).

    Research areas

  • GWAS meta-analysis, Latino population, Polygenic score, TOPMed imputation, Type 2 diabetes

ID: 350992820